Statements (75)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:administered_by |
oral tablet
|
| gptkbp:approves |
gptkb:2011
gptkb:FDA |
| gptkbp:atccode |
L01 XE14
|
| gptkbp:brand |
gptkb:Jakafi
|
| gptkbp:casnumber |
941678-49-5
|
| gptkbp:category |
gptkb:C
not recommended |
| gptkbp:chemical_formula |
C17 H18 N4 O5 P
|
| gptkbp:clinical_trial |
Phase III
NCT04512345 NCT03012345 NCT03412345 NCT04212345 NCT03512345 NCT04012345 NCT01243944 NCT01832118 NCT02055781 NCT02158858 NCT02296476 NCT02300016 NCT02445650 NCT02531824 NCT02612311 NCT02712345 NCT02812345 NCT02912345 NCT03112345 NCT03212345 NCT03312345 NCT03612345 NCT03712345 NCT03812345 NCT03912345 NCT04112345 NCT04312345 NCT04412345 NCT04612345 NCT04712345 NCT04812345 NCT04912345 |
| gptkbp:clinical_use |
hematological malignancies
|
| gptkbp:contraindication |
active infections
severe hepatic impairment |
| gptkbp:discovered_by |
gptkb:Incyte_Corporation
|
| gptkbp:drug_interactions |
live vaccines
strong CYP3 A4 inducers |
| gptkbp:excretion |
urine
|
| gptkbp:formulation |
gptkb:tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ruxolitinib
|
| gptkbp:indication |
gptkb:polycythemia_vera
myelofibrosis |
| gptkbp:invention |
patented
|
| gptkbp:lifespan |
3 hours
|
| gptkbp:marketed_as |
gptkb:Incyte_Corporation
gptkb:Australia gptkb:Canada gptkb:European_Union gptkb:United_States |
| gptkbp:mechanism_of_action |
JAK1 and JAK2 inhibitor
|
| gptkbp:metabolism |
liver
|
| gptkbp:research |
autoimmune diseases
|
| gptkbp:route_of_administration |
oral
|
| gptkbp:side_effect |
gptkb:anemia
increased risk of infections thrombocytopenia elevated liver enzymes |
| gptkbp:storage |
room temperature
|
| gptkbp:targets |
gptkb:Cyclin-dependent_kinase
|
| gptkbp:used_for |
treatment of myelofibrosis
treatment of polycythemia vera |
| gptkbp:bfsParent |
gptkb:EMD_Serono
|
| gptkbp:bfsLayer |
5
|